Oramed Pharmaceuticals Reaches Analyst Target Price
September 27, 2021 at 09:44 AM EDT
In recent trading, shares of Oramed Pharmaceuticals Inc (ORMP) have crossed above the average analyst 12-month target price of $22.50, changing hands for $22.69/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..